Business Context and Reporting Period
This Form 6-K filing by Immunocore Holdings Plc covers the month of December 2022, specifically dated December 2, 2022. The report serves to incorporate a press release by reference into the Company's registration statements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a corporate event rather than a financial statement.
Material Changes
The primary material change disclosed is the announcement of a new collaboration with Gadeta B.V. to develop a gamma delta ImmTAC candidate targeting solid tumors.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors beyond the general context of the new collaboration. The press release detailing the partnership is furnished as Exhibit 99.1 but is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Points
- Review the full text of the press release (Exhibit 99.1) for specific terms of the Gadeta B.V. collaboration.
- Verify the strategic fit of the gamma delta ImmTAC candidate within Immunocore's existing pipeline.
- Check subsequent filings for any financial impact or milestone payments related to this new partnership.